Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation.

Area of Science:

• Biochemistry
• Computational Biology
• Pharmacology

Background:

• Metformin is proposed to activate SIRT1, a NAD+-dependent deacetylase.
• SIRT1 mimics metabolic effects of calorie restriction.
• Understanding metformin's mechanism is crucial for its health benefits.

Purpose of the Study:

• To investigate the molecular interactions between metformin and SIRT1 using in silico methods.
• To delineate the binding modes of metformin to human SIRT1.
• To confirm the biochemical effects of metformin on SIRT1 activity.

Main Methods:

• In silico analysis including molecular docking and dynamic simulation.
• Utilized eight different crystal structures of human SIRT1.
• Performed enzymatic assays with metformin and phenformin.

Main Results:

• Metformin predicted to bind to allosteric and NAD+ binding sites of SIRT1.
• Binding occurs at the C-terminal regulatory segment, potentially activating SIRT1.
• Enzymatic assays confirmed improved SIRT1 catalytic efficiency with metformin, especially in low NAD+ conditions.

Conclusions:

• Metformin's interactions with SIRT1 support its role as a direct SIRT1-activating compound.
• Findings offer insights into metformin's health benefits via SIRT1 maintenance during aging.
• Further studies needed to confirm mechanistic relevance of predicted binding modes.